Skip to main content

Newsroom

Newsroom

2017

  • May 24, 2017
    OrphoMed Secures $39 Million Series A Financing Round
  • May 15, 2017
    BiomX Raises $24 Million in Series A Funding to Develop Microbiome Therapeutics

2016

  • August 1, 2016
    Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
  • January 6, 2016
    Cortexyme Raises $15 Million Series A

2015

  • October 23, 2015
    Univercells SA Enters Strategic Partnership with Takeda Pharmaceutical Company, Limited to Produce Affordable Vaccines for Developing Countries
  • August 20, 2015
    Presage Biosciences Receives Strategic Investment from Takeda
  • July 26, 2015
    Allergan to Acquire Naurex
  • February 23, 2015
    Sosei Acquires Heptares Therapeutics for up to USD 400 million
  • January 27, 2015
    Naurex's First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement in Depression Scores within 24 Hours in Phase 2 Study for Major Depressive Disorder

2014

  • December 20, 2014
    OneStart 2015 Semi-finalists Announced
  • December 10, 2014
    Naurex's GLYX-13 Demonstrates Robust, Sustained Antidepressant Effects and Excellent Tolerability in Phase 2b Study
  • December 3, 2014
    December 3, 2014: Naurex Raises $80 Million in Series C Financing to Advance Novel NMDA Receptor Modulators in Depression and Other CNS Disorders.
  • November 10, 2014
    Xenon Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
  • October 2, 2014
    Redwood Bioscience, Inc. Acquired by Catalent Pharma Solutions
  • September 25, 2014
    BioMotiv and Takeda Pharmaceutical Company Enter into Strategic Partnership
  • August 14, 2014
    Juventas Therapeutics completes enrollment of Phase I/II RETRO-HF trial and demonstrates safety for retrograde infusion of JVS-100 in patients with heart failure
  • July 23, 2014
    ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome
  • July 7, 2014
    Heptares Announces Publication in Nature of First Structure of Metabotropic Glutamate Receptor 5 Transmembrane Domain
  • March 31, 2014
    Hookipa Biotech wins Best Financial Deal Award in the Vaccine Industry Excellence (ViE) Awards 2014
  • March 12, 2014
    Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA® for the Treatment of Hematologic Malignancies

2013

  • November 4, 2013
    Hookipa Biotech Closes €20 Million ($27.5 Million) in Series B Financing
  • October 1, 2013
    Fate Therapeutics, Inc. announces pricing of initial public offering
  • July 18, 2013
    NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
  • July 17, 2013
    Heptares Announces Publication in Nature of Class B GPCR Structure
  • June 27, 2013
    Heptares raises US$21 million to advance novel GPCR medicines into clinical development
  • June 25, 2013
    CellCentric gains £4.3m to take prostate cancer programme through to clinical candidates.
  • June 2, 2013
    Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody
  • May 2, 2013
    Symphogen Expands Previous Private Equity Round, Reaching a Total of € 141 million (USD 185 million)
  • April 28, 2013
    Heptares achieves all research milestones and receives milestone payment from GPCR drug discovery agreement with Takeda
  • March 18, 2013
    Heptares StaRs® enable ‘reverse pharmacology’ approach to accelerate GPCR-focused drug discovery

2012

  • December 17, 2012
    Naurex Completes $38 Million Series B Financing
  • December 6, 2012
    Redwood Bioscience Announces The Appointment of Gordon Foulkes, PhD as Executive Chairman
  • November 9, 2012
    ArmaGen Technologies, Inc. Announces $17 Million Series A Financing
  • November 13, 2012
    Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer's Disease
  • November 6, 2012
    Takeda to Acquire Envoy Therapeutics, Inc.
  • November 5, 2012
    Domainex announces that compounds from its IKKepsilon programme have activity against the IL-17 signaling pathway
  • October 15, 2012
    Fate Therapeutics Appoints Christian Weyer as President and Chief Executive Officer
  • July 16, 2012
    Juventas Therapeutics announces it has closed a $22.2 million Series B financing
  • May 7, 2012
    Michael J. Fox Foundation Expands Funding to Envoy

2011

  • December 14, 2011
    Fate Therapeutics announces the appointment of William H. Rastetter as Chairman and Interim CEO
  • November 7, 2011
    Naurex's Novel Antidepressant GLYX-13 Recognized As One of Windhover's 2011 Top 10 Neuroscience Projects to Watch
  • June 27, 2011
    Redwood Bioscience Secures Funding for Optimized Conjugate Drug Development
  • May 11, 2011
    Naurex Completes $18 Million Series A Financing
  • May 9, 2011
    Takeda Ventures makes strategic investment in Fate Therapeutics –Joins strategic investor syndicate of Fate that includes four pharmaceutical companies
  • April 11, 2011
    Heptares and Takeda Initiate Drug Discovery Collaboration Focused on GPCR linked to CNS Disorders
  • March 14, 2011
    CellCentric Closes First Tranche of Series B Financing
  • January 6, 2011
    Symphogen Raises €100 Million in Private Equity Round

2010

  • October 19,2010
    Patrys initiates clinical studies in melanoma patients with PAT-SM6, a natural human antibody against GRP78
  • October 08,2010
    Takeda and Envoy Form Schizophrenia Research Alliance
  • September 16, 2010
    Symphogen Announces Publication of Data on the Manufacture of Polyclonal Antibodies Developed Using Sympress™ Technology
  • August 31,2010
    CellCentric's Scientific Founder Awarded Royal Medal
  • Feb 22, 2010
    CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda Pharmaceutical Company, Ltd
  • Feb 18, 2010
    Domainex Ltd Announces Investment From Takeda Research Investment, Inc
  • Jan 26, 2010
    Envoy Therapeutics, Inc. today announced that it has entered into a multi-year research collaboration agreement with an affiliate of Merck & Co., Inc. to discover novel diabetes and obesity drug targets. For full details, please click here here.
  • Jan 25, 2010
    CellCentric, the biotechnology company unlocking epigenetic control mechanisms, has an ongoing research relationship with Prof. Wolf Reik at the Babraham Institute, Cambridge. New work from his lab published today in Nature, highlights the substantial degree to which DNA demethylation occurs in early mammalian development and that AID is a critical component of the process. It builds upon Wolf Reik's earlier work on the biochemistry of AID's activities in cells. For full details, please click here here.

2009

  • Nov 11, 2009
    Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced that it has secured a loan from Takeda Research Investment (TVI) which Envoy may elect to convert to Envoy preferred stock should the company complete a second private equity financing. TVI will receive certain rights from Envoy related to a specific therapeutic field while scientists at the two companies craft a broad scientific research alliance. For full details, please click here.
  • Oct 14, 2009
    Envoy Therapeutics, a new drug discovery company based in Jupiter FL, announces the successful closing of its first financing, an $8 million private placement of the company's Series A Preferred Stock. Led by 5AM Ventures, other investors participating in the financing included Takeda Research Investment and Roche Venture Fund. For full details, please click here.
  • Jun 02, 2009
    CellCentric announces that the company is hosting a conference and celebration of Imprinting and Epigenetics, at the University of Cambridge on September 4-6th 2009. For full details, please click here.